689 results about "Adenocarcinoma cell" patented technology

The present invention relates to oncogenes or tumor suppressor genes, as well as other genes, involved in prostate cancer and their expression products, as well as derivatives and analogs thereof. Provided are therapeutic compositions and methods of detecting and treating cancer, including prostate and other related cancers. Also provided are methods of diagnosing and / or prognosing prostate cancer by determining the expression level of at least one prostate cancer-cell-specific gene, including, for example, the ERG gene or the LTF gene alone, or in combination with at least one of the AMACR gene and the DD3 gene.

The present invention discloses a medicine with actions of resisting plant virus and resisting tumor-N-substituted benzothiazolyl-1-substituted phenyl-0.0-dialkyl-alpha- aminophosphonates derivative, its preparation method and biological activity. Said invention also provides its structure formula, and also provides its extensive application for inhibiting tobacco mosaic virus (TMV) activity and inhibiting activity of human body prostatic cancer cell PC3 and others.

The present invention includes a method of utilizing four peptide hormones to inhibit the growth of cancer(s). A dramatic decrease in the number of human pancreatic adenocarcinoma cells (i.e., the type of cancer with the highest mortality, with patients only surviving four months) was observed responsive to treatment. The application of the invention would be to utilize one or more of these peptide hormones alone and / or in combination to treat cancer. The ability of these peptide hormones to decrease the number of adenocarcinoma cells has implications for adenocarcinomas at other sites in the body with the majority of cancers of the breast, colon and prostate also being adenocarcinomas. Adenocarcinomas also occur in the lung and other tissues. Treatment of a wide variety of cancers in addition to adenocarcinomas is anticipated by the present invention.

The invention provides a reagent for diagnosing cervical cancer, which can not only detect the presence or absence of cervical cancer but can also distinguish squamous cell carcinoma and adenocarcinoma from each other, a method for screening cervical cancer by using the reagent, particularly a screening method capable high speed processing by utilizing flow cytometry. The reagent comprises a first labeled antibody reacting with gland cells, a second labeled antibody reacting with adenocarcinoma cells and a third labeled antibody reacting with atypical cervical squamous cells, the antibodies being labeled with mutually distinguishable labels respectively. Preferably, at least one selected from the group consisting of MUC1 antibody, cytokeratin 7 antibody, and cytokeratin 18 antibody is used as the first labeled antibody, at least one selected from the group consisting of cytokeratin 8 antibody and HIK1083 antibody is used as the second labeled antibody, and at least one member selected from the group consisting of NMP179 antibody, p16INK4A antibody, Ki-67 antibody, p53 antibody, p21 antibody, EMA antibody, CEA antibody and MIB-1 antibody is used as the third labeled antibody.

Methods and compositions are disclosed for inhibiting proliferation of human colon adenocarcinoma cells, reducing pro-inflammatory molecules, adhesion molecules, and vascular smooth muscle cell proliferation, and for increasing NO production. The present invention describes the use of phenolic compositions, purified from oats or synthetically produced, to decrease the effective amount of pro-inflammatory molecules and / or cell adhesion molecules. Alternatively, an alcoholic extract or concentrate from oats can be used. The methods of the present invention can be used as a treatment or prophylaxis of a wide variety of disorders associated with inflammatory states and / or with a lack of or need for nitric oxide (NO), such as inflammatory conditions, pain, free radical associated disorders, cardiovascular diseases, autoimmune disorders, pathological platelet aggregation, pathological vasoconstriction, vascular effects of diabetes, stroke, atherosclerosis, hypertension, abnormal vasospasm, and restenosis after angioplasty.

The invention provides a reagent for diagnosing cervical cancer, which can not only detect the presence or absence of cervical cancer but can also distinguish squamous cell carcinoma and adenocarcinoma from each other, a method for screening cervical cancer by using the reagent, particularly a screening method capable high speed processing by utilizing flow cytometry. The reagent comprises a first labeled antibody reacting with gland cells, a second labeled antibody reacting with adenocarcinoma cells and a third labeled antibody reacting with atypical cervical squamous cells, the antibodies being labeled with mutually distinguishable labels respectively. Preferably, at least one selected from the group consisting of MUC1 antibody, cytokeratin 7 antibody, and cytokeratin 18 antibody is used as the first labeled antibody, at least one selected from the group consisting of cytokeratin 8 antibody and HIK1083 antibody is used as the second labeled antibody, and at least one member selected from the group consisting of NMP179 antibody, p16[INK4A] antibody, Ki-67 antibody, p53 antibody, p21 antibody, EMA antibody, CEA antibody and MIB-1 antibody is used as the third labeled antibody.

The present invention relates to epitope of CD66c specific to lung adenocarcinoma and antibody recognizing the same. The present invention relates to identifying epitope of CD66c specific to lung adenocarcinoma, antibody recognizing the same, cell lines producing the same and the applications in diagnosis, prevention and treatment of lung adenocarcinoma by using the same. The above CD66c epitope is specific to lung adenocarcinoma cells, and therefore the antibody or its fragment recognizing the epitope can be used in compositions to diagnose, treat and prevent lung adenocarcinoma cells.

A medicine combination has the function of resisting lung cancer. The combination is mixed with rhizoma paridis saponin and milk vetch root amylose according to the weight ratio of 3 to 1. The rhizoma paridis is extracted by alcohol and then the rhizoma paridis extract is obtained through gradient elutriation of macroporous absorption resin alcohol; the milk vetch root is extracted by water and then the protein is settled and removed to get the milk vetch root amylose; the two extracts are mixed and the medicine is made. The MTT activities experiment in vitro with the MTT method has proven that the medicine combination can obviously control the growth of various lung cancer cells such as LA795 lung adenocarcinoma cell and the IC50 can reach 26.73 ug / ml; the experiment of mouse with the lung cancer tumor has represented that the tumor constraint rate can reach 55.63 percent; in this way, lung transfer of hypodermic transplanted tumor of the mouse with the lung cancer tumor can be obviously controlled and the tumor cells can be brought to death; moreover, spleen index and thymus index can be promoted and the medicine is innocuous and has no side effect. In addition, compared with the raw materials, the medicine combination has high activity and clear function; moreover, the medicine can be made into different types.

The invention discloses a prostatic cancer related gene and application thereof. The gene is an N-myc downstream regulation type III gene (NDRG3). The NDRG3 has high expression in prostatic cancer tissues, and the over-expression of the gene can promote the proliferation of prostatic cancer cells and reduce the biological effect on the prostatic cancer cells. The reduction of the expression of the protein of the NDRG3 can obviously inhibit the growth of the prostatic cancer cells. Thus, the NDRG3 can be used as a novel target molecule for diagnosing and treating the prostatic cancer.

The present invention provides methods for preparing a gene expression profile of a breast cancer cell, tumor, or cell line, where the gene expression profile may be evaluated for one or more gene expression signatures indicative of multidrug resistance. The signature may be indicative of resistance to one or more chemotherapeutic agents selected from a Taxol (e.g., Docetaxel or Paclitaxel), an antibiotic (e.g., Doxorubicin or Epirubicin), an antimetabolite (e.g., Fluorouracil and / or Gemcitabine), and an alkylating agent (e.g., Cyclophosphamide). Generally, the gene expression profile contains the level of expression for a plurality of genes listed in FIGS. 3, 4, and / or 5. Gene expression profiles for evaluating multidrug resistance for ER positive and ER negative breast cancers are also provided.

The invention discloses an application of a gene marker in diagnosis and treatment of breast cancer. The gene is LINC02544, the invention firstly discovers that expression of LINC02544 in a breast cancer patient is obviously up-regulated, and verification is further carried out through QPCR, so that LINC02544 can be applied to diagnosis of the breast cancer as a biomarker. The invention also discloses that proliferation of breast cancer cells can be effectively inhibited and migration and attack rates of the breast cancer cells can be reduced by reducing expression of LINC02544, so that LINC02544 can be applied to treatment of the breast cancer and shift thereof as a drug target.

A mitochondria targeted gold nanoparticle (T-3-BP-AuNP) decorated with 3-bromopyruvate (3-BP) and delocalized lipophilic triphenylphosphonium (TPP) cations to target the mitochondrial membrane potential (Δψm) was developed for delivery of 3-BP to cancer cell mitochondria by taking advantage of higher Δψm in cancer cell compared to normal cells. This construct showed remarkable anticancer activity in prostate cancer cells compared to non-targeted construct NT-3-BP-AuNP and free 3-BP. Anticancer activity of T-3-BP-AuNP was further enhanced upon laser irradiation by exciting the surface plasmon resonance band of AuNP and thereby utilizing a combination of 3-BP chemotherapeutic and AuNP photothermal effects. T-3-BP-AuNPs showed markedly enhanced ability to alter cancer cell metabolism by inhibiting glycolysis and demolishing mitochondrial oxidative phosphorylation in prostate cancer cells. Our findings demonstrated that mitochondria targeted and concerted chemo-photothermal treatment of glycolytic cancer cells with a single NP may have promise as a new anticancer therapy.

The invention belongs to the technical field of chemical and pharmaceutical industry and particularly relates to the application of mogrol H9 for preparing antitumor drugs. The invention provides the application of mogrol H9 for preparing antitumor medicaments. The tumor cell can be liver cancer cell, leukaemia cell, cervical carcinoma cell, lung adenocarcinoma cell, stomach cancer cell, breast cancer cell or pancreatic cancer cell. The compound H9 is a natural product, has less toxic and adverse effects, high bioavailability and stable property, and is significant in clinical use. The small molecule compound is developed as a new antitumor drug or antitumor effective component, has an obvious antitumor effect, is green and environment-friendly, and provides a new approach to treatment and healing of tumors.

The present invention relates to the differential expression of genes in colorectal adenoma and adenocarcinoma cells and their correlation with chromosomal aberrations. The present invention provides tools for detecting chromosomal aberrations linked to progression of adenomas into adenocarcinoma cells. The present invention discloses methods and tools for in vivo and in vitro diagnosis of colorectal tumours.

The present invention relates to a pharmaceutical composition for the prevention and the treatment of cancers containing diaryl-isoxazole derivatives as an effective ingredient. Diaryl-isoxazole derivatives of the present invention inhibit metastasis of breast cancer cell lines and angiogenesis, so that they can be produced as a metastasis inhibitor and further as a pharmaceutical composition for the prevention and the treatment of angiogenesis related diseases including cancers, rheumatoid arthritis, psoriasis, or angiogenesis diseases caused in eyeball, etc.

The invention discloses an aptamer for recognizing adriamycin-resistant breast cancer cells. The aptamer can be a single-stranded DNA molecule. Particularly, the aptamer can be an aptamer (1) formed by nucleotide molecules as shown in SEQ ID No. 1, an aptamer (2) formed by nucleotide molecules as shown in SEQ ID No. 2, an aptamer (3) formed by nucleotide molecules as shown in SEQ ID No. 3, an aptamer (4) formed by nucleotide molecules as shown in SEQ ID No. 4, an aptamer (5) formed by nucleotide molecules as shown in SEQ ID No. 5 and an aptamer (6) formed by nucleotide molecules as shown in SEQ ID No. 6. By adopting the aptamer disclosed by the invention, the resistance to medicines of tumors can be monitored in real time according to molecular response signals under the condition that the medicine resistance mechanism is unknown so that the treatment scheme can be changed timely and the success rate of chemotherapy can be increased.

The invention discloses a method for culturing lung cancer stem cells under 3D culture conditions and belongs to the field of cell culture methods. The method comprises the following steps of placing human lung adenocarcinoma cell line A549 in an incubator for culturing with a RPMI-1640 complete culture medium containing 10% fetal calf serum, taking a cell suspension in a logarithm growth period, adjusting the concentration of the cells to 5*10<4>cells / ml and adding 200 mu L / well into a 96-well plate in which 50 mu L / well BME is spread; on the third day, changing the culture medium for the A549 cells with a RPMI-1640 complete culture medium containing IGF-1 and FGF and further culturing; digesting BME through a proteolytic enzyme, recovering the A549 cells from a recovery liquid and finally identifying the cells. By such design, the A549 cells form cloned mass similar to in-vivo tumor mass in vitro, which is closer to the three-dimensional growth state in the human body and thus the stable separation and effective amplification of stem cells are achieved. The cancer stem cells capable of resisting anticancer drugs are screened.

The invention discloses a fusion protein of Her2 antibody and interleukin 2 and application thereof, and belongs to the technical fields of medical science and oncology phymatology. The fusion protein comprises CD16 monoclonal antibody heavy chain signal peptide, ErbB2 antibody heavy chain variable region, a Linker 1, a light chain variable region, a human antibody Fc segment, a Linker 2 and IL-2 mature peptide, and has the amino acid sequence shown as SEQ ID No.1. The fusion protein can inhibit Herceptin resistant breast cancer cell proliferation, and can kill Her2 high-expression breast cancer cells. The invention lays a foundation for clinical application of the fusion protein of the Her2 antibody and the interleukin 2 in the anti-tumor aspect.

The invention discloses a marker for diagnosing and treating lung adenocarcinoma. The PLD5 gene is highly expressed in lung adenocarcinoma tissues, the inhibition of the expression of the PLD5 gene can promote the apoptosis of lung adenocarcinoma cells. The expression level of the PLD5 gene in the lung tissues can be detected to sensitively and specifically diagnose lung adenocarcinoma. The invention also provides a treatment means for lung adenocarcinoma.

The invention discloses an application of a Lnc03729 gene c as a biomarker in the preparation of markers for diagnosis, prognosis evaluation and therapeutic guidance of lung adenocarcinoma. RNA is extracted from lung adenocarcinoma and normal lung tissue samples and is reversely transcribed, the expression of Lnc03729 is detected through a real-time fluorescent quantitative PCR technology, the expression of human lung adenocarcinoma cell Lnc03729 is exogenously up-regulated, and the change of the proliferation and the metastasis of the cells is detected through MTS and Transwell experiments. Aresult shows that the Lnc03729 is under-expressed in the lung adenocarcinoma tissues, and the up-regulation of the expression of the human lung adenocarcinoma cells Lnc03729 significantly down-regulates the proliferation and metastasis ability of the cells, so it is prompted that the Lnc03729 can be used as a marker for the malignancy and the patient prognosis evaluation of the lung adenocarcinoma cells. The application provides a powerful molecular biology tool for the auxiliary diagnosis, prognosis prediction and therapeutic guidance of the lung adenocarcinoma, and has far-reaching clinicalsignificance and important promotion and application prospects.

The invention discloses applications of FAM176A gene in diagnosis and treatment for rectum adenocarcinoma. The experiment proves that the FAM176A gene is in low expression in the tissue of the patient suffering from rectum adenocarcinoma; and the adding of the expression of FAM176A can inhibit the proliferation of rectum adenocarcinoma cells and promote the apoptosis of the rectum adenocarcinoma cells. According to the invention, a diagnosis means for the rectum adenocarcinoma is discovered, and meanwhile, a novel target spot is provided for the gene therapy of the rectum adenocarcinoma.

The invention discloses siRNA (small interfering ribonucleic acid) for specifically inhibiting human ER81 gene expression, and a preparation method and screening method of siRNA. An ER81 gene is used as a target point sequence, and aiming at the homologous sequence of seven transcription mutant coding regions of the gene, an interference target point is selected from each of the upstream side, the midstream side and the downstream side so as to construct three recombinant siRNA expression vectors. The siRNA recombinant expression vectors is transferred into a breast cancer cell line MDA-MB-231 and an siRNA segment which can be used for obviously inhibiting the ER81 gene expression is finally screened out by using a DNA (deoxyribonucleic acid)-mediated RNA interfering technology. Experimental results show that screened siRNA can be used for specifically and efficiently inhibiting the ER81 gene expression so as to inhibit the proliferation of the breast cancer cells and promote cell apoptosis. Screened siRNA disclosed by the invention provides a new way for preparing related medicaments for treating breast cancers and shows good application prospects.

The invention discloses a benzimidazole-containing Tr*ger's base type compound as well as a preparation method and application thereof. A structural formula of the compound is shown as a formula 3; the compound is prepared by carrying out aldimine condensation reaction on 2,8-dialdehyde-Tr*ger's base and substituted o-phenylenediamine. An in-vivo experiment shows that the benzimidazole-containingTr*ger's base type compound has relatively high inhibition activity on non-small cell lung cancer cells (A549), triple-negative breast cancer cells (231) and triple-positive breast cancer cells (MCF-7), and has low toxicity in human normal cells; the benzimidazole-containing Tr*ger's base type compound can be mixed with human body acceptable acid-forming salt or a medical carrier to form an anti-tumor drug. The invention provides a candidate compound for researching and developing a novel drug for treating triple-negative and triple-positive breast cancer and non-small cell lung cancer. The formula 3 is shown in the description.

The invention provides a 2-aminoimidazopyridine derivative shown as a formula I, a formula II, a formula III or a formula IV and further provides a preparation method and application of the 2-aminoimidazopyridine derivative. An experiment shows that the 2-aminoimidazopyridine derivative has a remarkable proliferation inhibition effect on tumor cells (including an over-expressed wild type EGFR (Epidermal Growth Factor Receptor) human epidermal carcinoma cell line A431 and a Gefitinib drug-resisting human lung adenocarcinoma cell line H1975) related to the activity of EGFR tyrosine kinase in the aspect of a cell level, especially has a relatively good inhibition effect on the drug-resisting cell line H1975, has relatively weak inhibition activity on a low-expression EGFR human colon cancer cell line SW620 and can be applied to preparation of corresponding anti-tumor cell medicines. A general formula is shown in the description.

The invention relates to a vincristine-reversion agent compound nano particle, a preparation thereof and applications, belonging to the medicine field. A first technical problem to be solved by the invention is: overcoming the phenomena of multidrug resistance MDR of various tumor cells to the vincristine, namely, the vincristine and the reversion agent are wrapped and carried in a PLGA in a compound way, for preparing the nano particles. With the purposes of obtaining the smaller-diameter nano particles and reducing the vestigital of the surface active agent, F68 and TPGS are adopted as the surface active agent; compared with PVA, the TPGS and the F68 can obviously increase the mortality of drug-resistant breast cancer cells (p is smaller than 0.05); and the tumor-inhibition rate of the TPGS is obviously higher than that of the F68.

The invention discloses a compound lithocarolsA-F, a preparation method and application thereof in preparation of antitumor drugs. The compound lithocarolsA-F is isolated from a fermentation culture of marine fungi Phomopsis lithocarpus FS508. Experiments prove that the IC50 values of the compound lithocarolsA-F on liver cancer cells HepG-2, breast cancer cells MCF-7, glioma cells SF-268 and non-small cell lung cancer cells A549 are 10.5-87.7 muM, showing that the compound lithocarolsA-F has relatively significant antitumor activity and can be used for preparing antitumor drugs.

The invention provides a method for establishing orthotopic transplantation model of colorectal cancer, which comprises a) selecting and culturing colon adenocarcinoma cell line and preparing cell suspension; b) performing colostomy on living experimental animal; c) and inoculating the above colon adenocarcinoma cell suspension to submucosal stroma to allow natural growth. The biological traits such as route of metastasis of the transplanted adenocarcinoma cells are similar to that of the primary colon adenocarcinoma cell. The invention is advantageous in that the model is easy to be established, the transplanted colon adenocarcinoma locates at body surface so that it can be sampled and observed conveniently to meet the requirement for dynamic research, and the consumption of experimental animals can be reduced.

The invention discloses an application of lncRNA (long no-coding RNA) which is LINC01983 in diagnosis and tretament of lung adenocarcinoma. Significant up-regulation of expression of the LINC01983 inlung adenocarcinoma is found for the first time, and large-sample QPCR experiments further prove that the LINC01983 can be applied to clinical diagnosis of the lung adenocarcinoma as a potential molecular target. The invention also discloses the LINC01983 related to proliferation, migration and invasion of lung adenocarcinoma cells, which indicates that the LINC01983 can be applied to clinical diagnosis of the lung adenocarcinoma as the potential molecular target.